In the recent 4C / Company Update there is (again) mention of Epichem designing its own formulation of Monepantel (MPL) with improved qualities. In addition it is noted that a new formulation would be wholly owned by PAA.
As Novartis are the owners of the existing MPL formulation would this force their hand to exercise option with PAA? Taking the perspective of Novartis, surely there would be an attraction to exercise the option and buy into the arrangement, or sit back and watch Epichem produce a superior product of which they have no control and reap no benefit.
Is this a logical train of thought?
Strategy
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $87.51M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.3¢ | 17.5¢ | $205.5K | 1.150M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 55777 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 56756 | 2 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |